Stock Scorecard
Stock Summary for Mind Medicine Inc (MNMD) - $13.58 as of 1/5/2026 8:27:36 PM EST
Total Score
8 out of 30
Safety Score
39 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for MNMD
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for MNMD
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for MNMD
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for MNMD
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for MNMD (39 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for MNMD
Financial Details for MNMD
Company Overview |
|
|---|---|
| Ticker | MNMD |
| Company Name | Mind Medicine Inc |
| Country | USA |
| Description | Mind Medicine (MindMed) Inc. is a pioneering biotechnology company based in New York, specializing in psychedelic-inspired therapies for addiction and mental health disorders. The firm is at the forefront of developing evidence-based treatments through rigorous clinical trials and innovative research, aiming to address the increasing global mental health crisis. By integrating advanced psychedelics into therapeutic protocols, MindMed is strategically positioned as a leader in the expanding field of psychedelic medicine, making it an attractive opportunity for institutional investors seeking to engage with transformative advancements in healthcare. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/5/2026 |
Stock Price History |
|
| Last Day Price | 13.58 |
| Price 4 Years Ago | 2.20 |
| Last Day Price Updated | 1/5/2026 8:27:36 PM EST |
| Last Day Volume | 3,075,921 |
| Average Daily Volume | 1,861,088 |
| 52-Week High | 14.43 |
| 52-Week Low | 4.70 |
| Last Price to 52 Week Low | 188.94% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 21.56 |
| Sector PE | 52.63 |
| 5-Year Average PE | -3.57 |
| Free Cash Flow Ratio | 64.67 |
| Industry Free Cash Flow Ratio | 20.87 |
| Sector Free Cash Flow Ratio | 30.62 |
| Current Ratio Most Recent Quarter | 3.30 |
| Total Cash Per Share | 0.21 |
| Book Value Per Share Most Recent Quarter | 1.70 |
| Price to Book Ratio | 10.10 |
| Industry Price to Book Ratio | 4.22 |
| Sector Price to Book Ratio | 38.88 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.90 |
| Sector Price to Sales Ratio Twelve Trailing Months | 11.30 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 97,219,000 |
| Market Capitalization | 1,320,234,020 |
| Institutional Ownership | 41.62% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -13.52% |
| Reported EPS 12 Trailing Months | -1.98 |
| Reported EPS Past Year | -1.63 |
| Reported EPS Prior Year | -2.08 |
| Net Income Twelve Trailing Months | -168,098,000 |
| Net Income Past Year | -108,679,000 |
| Net Income Prior Year | -95,732,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 19,959,000 |
| Total Cash Past Year | 273,741,000 |
| Total Cash Prior Year | 99,704,000 |
| Net Cash Position Most Recent Quarter | -20,426,000 |
| Net Cash Position Past Year | 251,887,000 |
| Long Term Debt Past Year | 21,854,000 |
| Long Term Debt Prior Year | 14,129,000 |
| Total Debt Most Recent Quarter | 40,385,000 |
| Equity to Debt Ratio Past Year | 0.92 |
| Equity to Debt Ratio Most Recent Quarter | 0.76 |
| Total Stockholder Equity Past Year | 241,448,000 |
| Total Stockholder Equity Prior Year | 78,134,000 |
| Total Stockholder Equity Most Recent Quarter | 130,596,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -113,936,004 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.17 |
| Free Cash Flow Past Year | -79,129,000 |
| Free Cash Flow Prior Year | -64,365,000 |
Options |
|
| Put/Call Ratio | 0.15 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.34 |
| MACD Signal | 0.30 |
| 20-Day Bollinger Lower Band | 8.47 |
| 20-Day Bollinger Middle Band | 11.62 |
| 20-Day Bollinger Upper Band | 14.78 |
| Beta | 2.80 |
| RSI | 52.35 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 1/3/2026 3:33:50 AM EST |